The LYCRA Company and Dukane Advance Ultrasonic Bonding for Nonwovens at INDEX™ 26

 LYCRA FUSION™ Fiber for Personal Care Applications Debuts

(BUSINESS WIRE)--The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the personal care industry, and Dukane, a manufacturer of ultrasonic bonding technologies for the hygiene and nonwovens market, are showcasing their latest co-developed advances in ultrasonic bonding at INDEX™ 26, taking place in Geneva, Switzerland, from May 19–22.

Since 2014, both companies have collaborated to advance ultrasonic bonding solutions that help diaper manufacturers improve product softness, fit, and performance while reducing energy consumption, material waste, and maintenance costs. Ultrasonic bonding creates bonded channels between two layers of nonwoven materials, mechanically securing elastic fibers without using adhesives. Dukane’s patented rotary and rigid ultrasonic bonding systems enable high-speed, adhesive-free assembly by delivering precisely controlled ultrasonic energy into nonwoven substrates.

LYCRA FUSION™ fiber, originally developed to prevent snags in hosiery from turning into runs, can now fuse to nonwoven layers during ultrasonic bonding. Its sheath/core construction fuses with surrounding materials, strengthens ultrasonic bonds, and delivers superior yarn creep (snapback). When this fiber is paired with Dukane’s advanced ultrasonic bonding modules, manufacturers can achieve precise elastic placement, improved bond integrity, and consistent product performance while eliminating the variability associated with hot-melt adhesives.

“As ultrasonic bonding gains traction in the hygiene industry, our longstanding collaboration with Dukane focuses on expanding technical capabilities while preparing for commercial scale-up,” said Doug Kelliher, executive vice president, product, The LYCRA Company. “We’re excited to introduce LYCRA FUSION™ fiber for personal care, which provides excellent performance with fewer breaking points and improved bond integrity during the ultrasonic bonding process.”

Building on this shared commitment to innovation, The LYCRA Company and Dukane are aligning fiber development with ultrasonic process engineering to support broader adoption of adhesive‑free elastic attachment in nonwovens.

“From ultrasonic lamination to precision sealing and cutting, our technologies are engineered for consistent quality, global scalability, and sustainable production,” said Justin Lafferty, global product development manager - nonwovens, Dukane. “By advancing ultrasonic bonding with LYCRA FUSION™ fiber, we’re helping customers improve product performance while enabling more efficient production.”

Explore more hygiene and nonwovens solutions at The LYCRA Company stand (2151) and the Dukane stand (1568) at INDEX™ 26.

About The LYCRA Company

The LYCRA Company innovates and produces fiber and technology solutions for the apparel and personal care industries and owns the leading consumer brands: LYCRA®, LYCRA HyFit®, LYCRA® T400®, COOLMAX®, THERMOLITE®, ELASPAN®, SUPPLEX® and TACTEL®. Headquartered in Wilmington, Delaware, U.S., The LYCRA Company is recognized worldwide for its sustainable products, technical expertise, and marketing support. The LYCRA Company focuses on adding value to its customers’ products by developing unique innovations designed to meet the consumer’s need for comfort and lasting performance. Learn more at thelycracompany.com.

About Dukane

Headquartered in St. Charles, DUKANE is a global leader in ultrasonic bonding technologies for the hygiene and personal care industries. Unlike single-approach bonding systems, Dukane offers a range of ultrasonic bonding modules designed to replace adhesive-based processes in hygiene and personal care manufacturing. Manufacturers can select the right bonding technology based on product design, production speed, and long-term operational goals. Dukane’s flexible platform supports intermittent and continuous bonding, as well as blade and rotary technologies, without locking manufacturers into a single technology path. Learn more at dukane.com/nonwoven.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260515514441/en/

Permalink

https://www.aetoswire.com/en/news/54536259

Contacts

 

Karie J. Ford

Karie.j.ford@lycra.com

Shivani Singh

ssingh@dukane.com

 

MOBX to Acquire U.S. Defense Rare Earth, Critical Minerals Company

 (BUSINESS WIRE)--Mobix Labs (Nasdaq: MOBX) today announced a non-binding Letter of Intent to acquire Special Project Delivery LLC ("SPD"), a U.S. company building sovereign supply chains for rare earth elements, critical minerals, and energy storage.

The proposed acquisition would extend Mobix Labs' national security work — already supplying U.S. and allied fighter jets, missiles, submarines, and satellites — directly into one of the world's most strategically important industrial sectors. MOBX is moving directly into the supply chain powering modern defense, aerospace, and AI infrastructure.

Forward-Looking Statements

This press release contains forward-looking statements regarding the proposed acquisition of Special Project Delivery LLC ("SPD"), which are subject to risks and uncertainties described in Mobix Labs' SEC filings and similar provisions under applicable non-U.S. securities laws. The Letter of Intent is non-binding, and there can be no assurance that a definitive agreement will be executed or the proposed transaction completed.

Follow us on X: @MobixLabs_MOBX

Follow on StockTwits: MobixLabs

Follow us on LinkedIn: Mobix Labs

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260514428219/en/

Permalink

https://www.aetoswire.com/en/news/1405202655082

Contacts

MOBX Investor Relations Contacts

Chris Eddy or David Collins

Catalyst IR

mobx@catalyst-ir.com or 212-924-9800

 

The Estée Lauder Companies & Puig End Discussions Regarding a Potential Business Combination

 The Estée Lauder Companies Reiterates Confidence in Its Beauty Reimagined Strategic Vision

(BUSINESS WIRE) -- On March 23, 2026, The Estée Lauder Companies Inc. (NYSE: EL) and Puig confirmed they were in discussions regarding a potential business combination, but unless and until an agreement was signed between the companies, there could be no assurances regarding the deal or its terms.

The Estée Lauder Companies and Puig today announced that the parties have terminated discussions regarding a potential business combination. The Estée Lauder Companies remains fully focused on continuing to execute its Beauty Reimagined strategy, which is well underway and delivering positive results.

“We are grateful for the conversations we have had with Puig,” said Stéphane de La Faverie, President and Chief Executive Officer of The Estée Lauder Companies. “Today, we are reiterating our confidence in the power of our incredible brands, our talented teams, and our strength as a standalone company. We are more optimistic than ever about our ability to unlock significant long-term value through Beauty Reimagined, and we remain focused on accelerating that progress.

We have one of the most powerful portfolios of prestige beauty brands in the world, supported by exceptional equity across categories, geographies, and consumer segments, and we believe we are uniquely positioned to drive sustainable long-term growth globally.

The momentum we are seeing across our business reinforces the strength of the path ahead. Through Beauty Reimagined and the implementation of our ‘One ELC’ operating model, we are building a faster, more agile, consumer-focused organization — one that is accelerating innovation, strengthening execution, scaling winning ideas globally, and investing behind the highest-growth opportunities across our portfolio.

At the same time, we will continue to evaluate and evolve our portfolio to ensure we have the right assets to drive the most compelling growth opportunities, including both potential acquisitions and divestitures.

We remain relentlessly focused on driving sustainable sales growth, expanding profitability, and delivering a solid double-digit adjusted operating margin over time, all while creating long-term value for stockholders.”

Forward-Looking Statements

The forward-looking statements in this press release, including those in the quoted remarks and those relating to the benefits and other expectations, involve risks and uncertainties. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Factors that could cause actual results to differ from those forward-looking statements include current economic and other conditions, including volatility, in the global marketplace, actions by retailers, suppliers and consumers, competition, and those risk factors described in The Estée Lauder Companies’ annual report on Form 10-K for the year ended June 30, 2025. The Estée Lauder Companies undertakes no obligation to update any forward-looking statements, except as required by law.

About The Estée Lauder Companies Inc.

The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, the DECIEM family of brands, including The Ordinary and NIOD, and BALMAIN Beauty.

ELC-C

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521769350/en/

Permalink

https://aetoswire.com/en/news/2205202655236

Contacts

Investor Relations:

Rainey Mancini

rmancini@estee.com

Media Relations:

Brendan Riley

briley@estee.com

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch

 ZUG, Switzerland - Saturday, 23. May 2026 AETOSWire Print 

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older

Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage

Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter

The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone

 

(BUSINESS WIRE) -- Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care.

This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care.

With the approval of Differin Epiduo OTC, Galderma is bringing its proven acne science to a broader population of acne sufferers through wider access to a dermatologist-recommended, prescription-strength treatment, while further strengthening its global leadership in acne care.

Delivering continued innovation in acne prevention and care

Differin Epiduo is a topical acne treatment that combines adapalene, a third-generation retinoid originally discovered and developed by Galderma to address the stability and tolerability challenges of earlier retinoids, with benzoyl peroxide (0.1/2.5%). This adapalene molecule reflects Galderma’s long-standing leadership in retinoid science, delivering an innovation-led approach that goes beyond traditional OTC acne actives. Together, these two dermatologist-trusted ingredients address key biological drivers of acne – clearing clogged pores, killing acne-causing bacteria, and reducing acne inflammation – to help clear acne, prevent future breakouts and improve skin tone, texture, and overall appearance.1,2

The formulation is further powered by its Simulgel™ Gel Base, which stabilizes and evenly distributes both active ingredients while maintaining benzoyl peroxide’s efficacy and improving overall tolerability. This enables a simple, one-pump, once-daily regimen – a level of ease that is critical to building consistent routines and achieving clearer skin over time.

 

“This approval marks an important milestone in acne care and reflects Galderma’s longstanding leadership in acne and retinoid science. Differin Epiduo pairs two complementary, evidence‑based actives: adapalene, a highly stable and well‑tolerated retinoid developed by Galderma, and benzoyl peroxide, a proven antimicrobial agent. This retinoid-benzoyl peroxide combination aligns with dermatology guidelines, which strongly recommend using both together as a first‑line, multimodal approach to acne treatment. Bringing this scientifically grounded combination to the OTC setting allows us to extend that legacy to patients across the U.S. while preserving the clinical rigor that underpins its effectiveness.”

 

BILL ANDRIOPOULOS, PH.D.

HEAD OF GLOBAL MEDICAL AFFAIRS

GALDERMA

 

Clinical data supporting the approval demonstrated:

Proven efficacy across multiple randomized, controlled Phase 3 studies, with adapalene/benzoyl peroxide gel consistently outperforming adapalene alone, benzoyl peroxide alone, and vehicle gel across inflammatory, non-inflammatory, and total acne lesions, as well as Investigator Global Assessment (IGA) success rates (“clear” or “almost clear”).3-5

Clinically meaningful improvement in lesion counts seen as early as Week 1, with antimicrobial activity beginning on Day 1 and up to 70.3% reduction in inflammatory acne lesions at Week 12.3

Sustained efficacy with long‑term use, maintaining ~65% total lesion reduction in a single arm study through 12 months, which supports once‑daily, ongoing acne control.6

Proven efficacy across diverse patient populations, with consistent results and favorable tolerability across skin tones.

 

“This milestone reflects a meaningful advancement for patients, as it expands access to a clinically proven, dual-active acne solution without the need for a prescription. In my practice, the combination of easy access and a simple, once-daily application can help patients use treatment more consistently in their treatment journey for the best possible outcomes.”

 

HEATHER WOOLERY-LLOYD, MD

BOARD-CERTIFIED DERMATOLOGIST

UNITED STATES

 

First approved as a prescription treatment, Epiduo® (Adapalene 0.1% and Benzoyl Peroxide 2.5%) Gel has been trusted by dermatologists for more than 15 years, with millions of prescriptions written worldwide. Its global clinical legacy includes more than ten Galderma studies involving over 3,200 patients, along with extensive third-party studies, across a wide range of ages, skin tones and acne severity. With this Prescription-to-OTC switch, Galderma continues to play a defining role in shaping modern acne care, leveraging its own proprietary science to advance dermatology, and expanding access to effective treatments.

Differin Epiduo will be available over-the-counter at most major retailers, including Walmart, Ulta, Target and Amazon, beginning in the summer of 2026. With a commitment to providing effective solutions across consumers’ acne journey, the Differin portfolio also includes cleansers, treatments, and moisturizers to support and provide wholistic solutions. For more information on Differin Epiduo and other Differin products, please visit www.differin.com and join the Differin community on Instagram, Facebook and YouTube to stay up to date on the latest innovations.

* Outside of the U.S. Epiduo® remains a prescription only product.

About Galderma

Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ—the skin—meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References:

Reynolds RV et al. J Am Acad Dermatol. 2024. doi:10.1016/j.jaad.2023.12.017.

Del Rosso JQ, J Clin Aesthet Dermatol. 2015.

Gollnick HP et al. Br J Dermatol. 2009;161(5):1180-1189.

Stein Gold L et al. Cutis. 2009;84(2):110-116.

Thiboutot DM et al. J Am Acad Dermatol. 2007;57(5):791-799.

Pariser et al JDD 2007 Sep;6(9):899-905.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522074280/en/

Permalink

https://www.aetoswire.com/en/news/2305202655273

Contacts

For further information:

Christian Marcoux, M.Sc.

Chief Communications Officer

christian.marcoux@galderma.com

+41 76 315 26 50

Céline Buguet

Franchises and R&D Communications Director

celine.buguet@galderma.com

+41 76 249 90 87

Viviana Wiewall

Head of U.S. Communications

viviana.wiewall@galderma.com

+1 786 451 7740

Emil Ivanov

Head of Strategy, Investor Relations, and ESG

emil.ivanov@galderma.com

+41 21 642 78 12

Jessica Cohen

Investor Relations and Strategy Director

jessica.cohen@galderma.com

+41 21 642 76 43

Global Stars Ahn Hyo-seop and Khalid Release New Cross-Market Single “Something Special” via FANDOM Today

 LOS ANGELES & SEOUL, South Korea - Friday, 22. May 2026 AETOSWire 

Produced by Woo “RAINSTONE” Rhee and Grammy Award-Winning Producer Troy “R8DIO” Johnson

Stream the Single HERE

For approved imagery, please download HERE

 

(BUSINESS WIRE)--Today marks the official release of “Something Special,” the highly anticipated cross-market collaboration from international star Ahn Hyo-seop and multi-platinum recording artist Khalid, available now via FANDOM on all major streaming platforms. Stream the single HERE. Musicow will also release an official music video in June, highlighting the unique chemistry between Ahn Hyo-seop and Khalid while bringing the song’s cross-cultural collaboration to life on screen.

Ahn Hyo-seop, globally recognized for his breakout role as “Jinu,” the leader of demon boy band Saja Boys in Netflix’s animated phenomenon KPop Demon Hunters, joins forces with Grammy-nominated artist Khalid for a genre-blending release that bridges the worlds of K-pop and U.S. R&B - two of the most influential forces shaping contemporary global music culture.

Produced by Woo “RAINSTONE” Rhee, known for his work on “Nobody” by legendary K-pop group Wonder Girls, and co-produced by Grammy Award-winning producer Troy “R8DIO” Johnson, whose credits include Solange’s critically acclaimed A Seat at the Table, “Something Special” delivers a sleek and emotionally resonant sound that highlights the unique artistry and international appeal of both performers.

The release marks several milestone moments: Ahn Hyo-seop’s debut official single as a solo artist and Khalid’s first-ever collaboration with a Korean artist. Together, the pair create a track designed to connect audiences across languages, cultures, and musical genres, reflecting the increasingly global and collaborative nature of today’s music industry.

Released under FANDOM and developed by Musicow in partnership with Roc Nation, “Something Special” advances the platform’s mission to redefine the connection between artists, music, and fans worldwide. Through interactive fan experiences, exclusive participation opportunities, and new ways to support the artists they love, FANDOM invites audiences deeper into the creative process.

The release follows FANDOM’s acclaimed January collaboration “Two Car Garage” from Jon Bellion and Swae Lee, further establishing the platform as a home for high-impact global collaborations and fan-driven music experiences.

“Something Special” is available now on all major streaming platforms. Additional fan engagement opportunities and exclusive content tied to the release will be announced via fndm.lnk.to/bio.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522928365/en/

Permalink

https://www.aetoswire.com/en/news/2205202655245

Contacts

MEDIA CONTACTS:

Jonah Keel | Jonah.Keel@42west.com

Greg Cortez | Greg.Cortez@42West.com

Amanda Pappalardo | Amanda.Pappalardo@42west.com

Ranese Southerland | Ranese.Southerland@42west.com

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX

 (BUSINESS WIRE) -- OKX, a blockchain technology and trading company serving more than 120 million customers globally, and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks.

The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure.

This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets.

ICE’s futures prices for Brent and WTI will underpin the new perpetual contracts offered on OKX’s platform. Brent Crude and WTI are among the world’s most widely referenced oil benchmarks.

"Oil markets are critical to the world economy. ICE’s Brent and WTI futures markets provide the benchmark prices that energy traders everywhere rely on. Bringing them into regulated perpetual futures is exactly the kind of bridge between traditional and digital markets that market participants have been asking for," said Haider Rafique, Global Managing Parter at OKX. "This launch gives retail traders access to the world's most important energy benchmarks in a regulated, transparent environment. That's a meaningful step forward as we modernize money and markets."

By integrating globally recognized commodity benchmarks into regulated digital markets, OKX and ICE are establishing new pathways for users to access some of the world’s most important energy markets.

“These new OKX perpetual contracts, based on ICE’s deep, liquid, transparent, and global oil markets, allow OKX’s customer base of 120 million retail traders to access energy benchmark products,” said Trabue Bland, Senior Vice President, Futures Exchanges at ICE.

The launch comes at a time of accelerating interest in tokenized finance, regulated derivatives and real-world asset products globally. For OKX, the launch reflects the company’s broader strategy of expanding regulated infrastructure and building products designed for long-term participation in global financial markets. OKX continues to invest in licensed market expansion, institutional infrastructure and products that bridge digital assets with traditional financial markets.

About OKX

OKX is a fintech company known for its global crypto trading platform and its on-chain wallet and marketplace. The company develops technology and applications to modernize money and markets. OKX is known for being one of the fastest and most reliable crypto and payment apps, having processed trillions of dollars in transactions by more than 120+ million people around the world.

OKX is headquartered in San Jose, California, for the Americas and in Dubai for the Middle East, with regional offices in São Paulo, New York, Hong Kong, Singapore, the Republic of Türkiye, Australia and Europe. Over the past several years, OKX has built one of the world's most comprehensive regulatory compliant, licensed crypto companies. It holds licenses in the United States, the UAE, EEA, Singapore and Australia, as well as in other markets.

OKX is steadfastly committed to transparency and security and publishes Proof of Reserves reports on a monthly basis. To learn more about OKX, download the app or visit: okx.com.

About Intercontinental Exchange

Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds, and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes helping our customers access mission-critical workflow tools that increase transparency and efficiency. ICE’s futures, equity, and options exchanges -- including the New York Stock Exchange -- and clearing houses help people invest, raise capital and manage risk. We offer some of the world’s largest markets to trade and clear energy and environmental products. Our fixed income, data services and execution capabilities provide information, analytics and platforms that help our customers streamline processes and capitalize on opportunities. At ICE Mortgage Technology, we are transforming U.S. housing finance, from initial consumer engagement through loan production, closing, registration and the long-term servicing relationship. Together, ICE transforms, streamlines, and automates industries to connect our customers to opportunity.

Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading “Key Information Documents (KIDS).”

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 -- Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2025, as filed with the SEC on February 5, 2026.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260522244272/en/

Permalink

https://www.aetoswire.com/en/news/2205202655262

Contacts

OKX Media Contact:

Dave Heinzinger

+1 646 430 4579

dave.heinzinger@okx.com

OKX Investor Relations Contact:

Elliott Suthers

+ 44 073777 220650

elliott.suthers@okx.com

ICE Media Contact

Damon Leavell

damon.leavell@ice.com

+1 212 323 8587

media@ice.com

ICE Investor Relations Contact:

Steve Eagerton

+1 904 854 3683

steve.eagerton@ice.com 

investors@ice.com

Polpharma Biologics and Tuteur Sign Licensing Agreement for a Biosimilar for Autoimmune Diseases

 ZUG, Switzerland - 

(BUSINESS WIRE)--Polpharma Biologics, a leading biopharmaceutical company specializing in the development and manufacturing of biosimilars, today announced the signing of a landmark licensing agreement with Argentina-based Tuteur. Under this strategic partnership, Tuteur will obtain exclusive rights to commercialize a biosimilar for autoimmune diseases across Latin America (LATAM), excluding Brazil.

Polpharma Biologics will retain full responsibility for the development and manufacturing of the biosimilar. Tuteur will be responsible for commercialization, marketing, and distribution in the licensed territories. This collaboration reflects a shared commitment to expanding patient access to high-quality, affordable biological therapies across the region.

“Partnering with Tuteur represents an important step in advancing our mission to broaden access to biosimilars globally,” said Anjan Selz, CEO of Polpharma Biologics. “With their strong regional expertise and commercial capabilities in LATAM, we are well-positioned to bring this important therapy to patients living with autoimmune diseases. Together, we aim to improve access to effective and affordable treatment options across the region.”

"Our collaboration with Polpharma Biologics marks a significant milestone for Tuteur," said Jonathan Hahn, President of Tuteur. "Partnering with an organization of their caliber reinforces our commitment to expanding access to world-class biologics for patients throughout Latin America."

The biosimilar, currently in development, is designed to provide an effective and well-tolerated treatment option for patients with autoimmune conditions. Regulatory submission is anticipated within the next three years.

About Polpharma Biologics

Polpharma Biologics is a group of biopharmaceutical companies focused on the development and manufacturing of biopharmaceuticals and biosimilars for global markets. Its Switzerland-based biosimilars platform manages the entire value chain—from product selection and investment allocation through development and commercialization—ensuring efficient progression from concept to launch in close collaboration with global partners. The company’s biosimilar portfolio spans multiple programs at various stages of development, from early-stage research to commercialization. Its international team brings deep expertise across program leadership, regulatory strategy, CMC integration, device development, clinical oversight, and quality assurance. Through Polpharma Biologics partnerships with trusted CDMOs, Polpharma Biologics delivers end-to-end biosimilar solutions, from cell line development to finished products, across key therapeutic areas. Polpharma Biologics is committed to accelerating access to biologic therapies worldwide by maintaining a robust and expanding pipeline of biosimilars.

More information: https://polpharmabiologics.com/polpharma-biologics-and-tuteur/

About Tuteur

Tuteur is a leading company in specialized medicine across Latin America, delivering innovative therapies and solutions that address complex medical needs. With a strong commitment to patient outcomes, operational excellence, and strategic partnerships, Tuteur combines deep expertise in manufacturing and distribution of specialty medicines to serve healthcare providers and patients across the region. Driven by a robust pipeline of specialized treatments and a patient-centric approach, Tuteur continues to expand its presence in LATAM while maintaining a focus on innovation, efficiency, and sustainable growth.

More information: https://tuteurgroup.com/

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20260521106271/en/

Permalink

https://aetoswire.com/en/news/2205202655247

Contacts

Media contact:

Natalia Kwiecień

natalia.kwiecien@polpharmabiologics.com